{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:49:23Z","timestamp":1792439363850,"version":"4.5.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2011-02349303"],"award-info":[{"award-number":["RF-2011-02349303"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.numecd.2022.02.016","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T02:20:33Z","timestamp":1646274033000},"page":"1320-1334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Turning the clock forward: New pharmacological and non pharmacological targets for the treatment of obesity"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-5547","authenticated-orcid":false,"given":"Anna","family":"Ferrulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Terruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Senesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Succi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cannavaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-0552","authenticated-orcid":false,"given":"Livio","family":"Luzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2022.02.016_bib1","author":"WHO"},{"issue":"2020","key":"10.1016\/j.numecd.2022.02.016_bib2","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.numecd.2022.02.016_bib3","series-title":"Health at a glance: Europe 2020: state of health in the EU cycle","article-title":"Obesity among adults","year":"2020"},{"key":"10.1016\/j.numecd.2022.02.016_bib4","doi-asserted-by":"crossref","first-page":"964236","DOI":"10.1155\/2014\/964236","article-title":"Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status?","volume":"2014","author":"Bhurosy","year":"2014","journal-title":"Sci World J"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S2213-8587(20)30001-2","article-title":"Tackling obesity in 2020-with a great resolution comes shared responsibility","volume":"8","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2022.02.016_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2022.02.016_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1467-789X.2009.00689.x","article-title":"Obesity is a sign \u2013 overeating is a symptom: an aetiological framework for the assessment and management of obesity","volume":"11","author":"Sharma","year":"2010","journal-title":"Obes Rev"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s11695-020-05160-5","article-title":"Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review","volume":"31","author":"El Ansari","year":"2021","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12902-020-0499-4","article-title":"Are there really any predictive factors for a successful weight loss after bariatric surgery?","volume":"20","author":"Cadena-Obando","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/ajcn\/nqaa349","article-title":"Reward-related gustatory and psychometric predictors of weight loss following bariatric surgery: a multicenter cohort study","volume":"113","author":"Ribeiro","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"16","key":"10.1016\/j.numecd.2022.02.016_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.21037\/atm.2019.07.27","article-title":"Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects","volume":"7","author":"Montan","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.numecd.2022.02.016_bib13","series-title":"Guidance for Industry: developing products for weight management","year":"2007"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrendo.2017.122","article-title":"Current pharmacotherapy for obesity","volume":"14","author":"Srivastava","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"Pt B","key":"10.1016\/j.numecd.2022.02.016_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.physbeh.2018.02.011","article-title":"Homeostatic and non-homeostatic controls of feeding behavior: distinct vs. common neural systems","volume":"193","author":"Liu","year":"2018","journal-title":"Physiol Behav"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib16","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/en.2007-1743","article-title":"Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation","volume":"149","author":"Hayes","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.numecd.2022.02.016_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2017.09.002","article-title":"An appetite for life: brain regulation of hunger and satiety","volume":"37","author":"Heisler","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.numecd.2022.02.016_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharmthera.2016.10.015","article-title":"Obesity: current and potential pharmacotherapeutics and targets","volume":"170","author":"Narayanaswami","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.numecd.2022.02.016_bib19","doi-asserted-by":"crossref","first-page":"190163","DOI":"10.1503\/jpn.190163","article-title":"The orbitofrontal cortex, food intake and obesity","volume":"45","author":"Seabrook","year":"2020","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/oby.2008.469","article-title":"Inverse association between BMI and prefrontal metabolic activity in healthy adults","volume":"17","author":"Volkow","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.numecd.2022.02.016_bib21","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.18632\/aging.102347","article-title":"High body mass index, brain metabolism and connectivity: an unfavorable effect in elderly females","volume":"11","author":"Sala","year":"2019","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9\u201310","key":"10.1016\/j.numecd.2022.02.016_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00213-016-4522-4","article-title":"Feeding-modulatory effects of mu-opioids in the medial prefrontal cortex: a review of recent findings and comparison to opioid actions in the nucleus accumbens","volume":"234","author":"Selleck","year":"2017","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ijo.2013.80","article-title":"The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options","volume":"38","author":"Fani","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.numecd.2022.02.016_bib25","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.peptides.2009.07.012","article-title":"Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL\/6J mice","volume":"30","author":"Kumar","year":"2009","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1210\/jc.2014-4024","article-title":"RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals","volume":"100","author":"Chen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2022.02.016_bib27","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib29","doi-asserted-by":"crossref","first-page":"E583","DOI":"10.1152\/ajpendo.00350.2002","article-title":"Chronic intracerebroventricular infusion of MCH causes obesity in mice. Melanin-concentrating hormone","volume":"284","author":"Gomori","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.numecd.2022.02.016_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nm741","article-title":"Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist","volume":"8","author":"Borowsky","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2022.02.016_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(02)01314-6","article-title":"T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist","volume":"438","author":"Takekawa","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.numecd.2022.02.016_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fendo.2012.00160","article-title":"Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models","volume":"3","author":"Della-Zuana","year":"2012","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.numecd.2022.02.016_bib33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/molecules26051291","article-title":"MCH-R1 antagonist GPS18169, a pseudopeptide, is a peripheral anti-obesity agent in mice","volume":"26","author":"Boutin","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/13543776.2014.993382","article-title":"Novel MCH1 receptor antagonists: a patent review","volume":"25","author":"Johansson","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.numecd.2022.02.016_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2013.07.009","article-title":"From preclinical to clinical development: the example of a novel treatment for obesity","volume":"61","author":"Moore","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.numecd.2022.02.016_bib36","first-page":"488","article-title":"The discovery of the MCH-1 receptor antagonist NGD-4715 for the potential treatment of obesity","volume":"8","author":"Tarrant","year":"2017","journal-title":"Compr Med Chem"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2125.2009.03550.x","article-title":"New central targets for the treatment of obesity","volume":"68","author":"Sargent","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib38","first-page":"1198","article-title":"Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs","volume":"4","author":"Levens","year":"2003","journal-title":"Curr Opin Invest Drugs"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","article-title":"Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults","volume":"4","author":"Erondu","year":"2006","journal-title":"Cell Metabol"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2022.02.016_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fphar.2018.00319","article-title":"Peripherally administered Y2-receptor antagonist BIIE0246 prevents diet-induced obesity in mice with excess neuropeptide Y, but enhances obesity in control mice","volume":"9","author":"Ailanen","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41467-021-21030-9","article-title":"Structural basis for ligand recognition of the neuropeptide Y Y2 receptor","volume":"12","author":"Tang","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11892-019-1211-9","article-title":"Pharmacological modulation of ghrelin to induce weight loss: successes and challenges","volume":"19","author":"Schalla","year":"2019","journal-title":"Curr Diabetes Rep"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2826.2007.01619.x","article-title":"The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin- but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus","volume":"20","author":"Becskei","year":"2008","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1210\/en.2005-0993","article-title":"Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice","volume":"147","author":"Shearman","year":"2006","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.mce.2011.01.010","article-title":"Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism","volume":"335","author":"Sangiao-Alvarellos","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib47","doi-asserted-by":"crossref","first-page":"R323","DOI":"10.1152\/ajpregu.00097.2013","article-title":"Anti-ghrelin Spiegelmer inhibits exogenous ghrelin-induced increases in food intake, hoarding, and neural activation, but not food deprivation-induced increases","volume":"305","author":"Teubner","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"10.1016\/j.numecd.2022.02.016_bib48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/gt.2015.38","article-title":"Neutralizing circulating ghrelin by expressing a growth hormone secretagogue receptor-based protein protects against high-fat diet-induced obesity in mice","volume":"22","author":"Gagnon","year":"2015","journal-title":"Gene Ther"},{"issue":"31","key":"10.1016\/j.numecd.2022.02.016_bib49","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.0805353105","article-title":"Inhibition of ghrelin Oacyltransferase (GOAT) by octanoylated pentapeptides","volume":"105","author":"Yang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6011","key":"10.1016\/j.numecd.2022.02.016_bib50","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1126\/science.1196154","article-title":"Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor","volume":"330","author":"Barnett","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib51","first-page":"493","article-title":"Treatment with the ghrelin-O-acyltransferase (GOAT) inhibitor GO-CoA-Tat reduces food intake by reducing meal frequency in rats","volume":"66","author":"Teuffel","year":"2015","journal-title":"J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acs.jmedchem.8b01644","article-title":"N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor","volume":"62","author":"M\u2019Kadmi","year":"2019","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.numecd.2022.02.016_bib53","doi-asserted-by":"crossref","first-page":"10796","DOI":"10.1021\/acs.jmedchem.9b02122","article-title":"Development of nonpeptidic inverse agonists of the ghrelin receptor (GHSR) based on the 1,2,4-triazole scaffold","volume":"63","author":"Haj Salah","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.numecd.2022.02.016_bib54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2022.02.016_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fendo.2014.00167","article-title":"New pharmacological perspectives for the leptin receptor in the treatment of obesity","volume":"5","author":"Roujeau","year":"2014","journal-title":"Front Endocrinol"},{"issue":"16","key":"10.1016\/j.numecd.2022.02.016_bib56","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib57","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1210\/endo.137.11.8895397","article-title":"A 35 amino acid fragment of leptin inhibits feeding in the rat","volume":"137","author":"Samson","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.numecd.2022.02.016_bib58","series-title":"Modified leptin polypeptides and their uses","author":"Vadim","year":"2009"},{"issue":"1\u20133","key":"10.1016\/j.numecd.2022.02.016_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-0115(01)00274-9","article-title":"[d-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL\/6J ob\/ob mice","volume":"101","author":"Grasso","year":"2001","journal-title":"Regul Pept"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib60","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1463-1326.2009.01189.x","article-title":"Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL\/6J wild-type and ob\/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels","volume":"12","author":"Novakovic","year":"2010","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib61","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/nu11112704","article-title":"Leptin, obesity, and leptin resistance: where are we 25 years later?","volume":"11","author":"Izquierdo","year":"2019","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1463-1326.2010.01243.x","article-title":"Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK\/6-m db\/db mice","volume":"12","author":"Waldrop","year":"2010","journal-title":"Diabetes Obes Metabol"},{"issue":"22","key":"10.1016\/j.numecd.2022.02.016_bib63","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1016\/j.bmcl.2010.08.130","article-title":"Novel thiazolidinedione derivatives with anti-obesity effects: dual action asPTP1B inhibitors and PPAR-\u03b3 activators","volume":"20","author":"Bhattarai","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib64","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/oby.2009.444","article-title":"Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice","volume":"18","author":"Lantz","year":"2010","journal-title":"Obesity"},{"key":"10.1016\/j.numecd.2022.02.016_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2008.12.004","article-title":"Endoplasmic reticulum stress plays a central role in development of leptin resistance","volume":"9","author":"Ozcan","year":"2009","journal-title":"Cell Metabol"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib66","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2337\/db10-0308","article-title":"Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women","volume":"59","author":"Kars","year":"2010","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib67","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/db10-1433","article-title":"Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans","volume":"60","author":"Xiao","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/en.2011-1586","article-title":"Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (DIO)","volume":"153","author":"Schulz","year":"2012","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2019.08.005","article-title":"Partial leptin reduction as an insulin sensitization and weight loss strategy","volume":"30","author":"Zhao","year":"2019","journal-title":"Cell Metabol"},{"key":"10.1016\/j.numecd.2022.02.016_bib70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin\u2014its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metabol"},{"issue":"9","key":"10.1016\/j.numecd.2022.02.016_bib71","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"S2","key":"10.1016\/j.numecd.2022.02.016_bib73","first-page":"18","article-title":"Efficacy and safety of AM833 for weight loss: a dose-finding trial in adults with overweight\/obesity","volume":"28","author":"Lau","year":"2020","journal-title":"Obesity"},{"issue":"10286","key":"10.1016\/j.numecd.2022.02.016_bib74","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2022.02.016_bib75","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10321","key":"10.1016\/j.numecd.2022.02.016_bib76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2022.02.016_bib77","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"472","key":"10.1016\/j.numecd.2022.02.016_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.numecd.2022.02.016_bib79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-811X-7-15","article-title":"Activin signaling as an emerging target for therapeutic interventions","volume":"7","author":"Tsuchida","year":"2009","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.numecd.2022.02.016_bib80","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1210\/en.2012-1016","article-title":"A novel therapeutic approach to treating obesity through modulation of TGF\u03b2 signaling","volume":"153","author":"Koncarevic","year":"2012","journal-title":"Endocrinology"},{"issue":"14","key":"10.1016\/j.numecd.2022.02.016_bib81","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/MCB.06575-11","article-title":"Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism","volume":"32","author":"Fournier","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib82","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib83","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/ggi.14265","article-title":"Blocking the activin IIB receptor with bimagrumab (BYM338) increases walking performance: a meta-analysis","volume":"21","author":"Spitz","year":"2021","journal-title":"Geriatr Gerontol Int"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib84","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nm873","article-title":"Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production","volume":"9","author":"Obici","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2022.02.016_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clnesp.2020.03.008","article-title":"Effects of l-carnitine supplementation on weight loss and body composition: a systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis","volume":"37","author":"Alenezhad","year":"2020","journal-title":"Clin Nutr ESPEN"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12020-018-1559-7","article-title":"The effect of L-carnitine supplementation on serum leptin concentrations: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Nazary-Vannani","year":"2018","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/nu13020373","article-title":"What role does the endocannabinoid system play in the pathogenesis of obesity?","volume":"13","author":"Schulz","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib88","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1172\/JCI97042","article-title":"Cannabis in fat: high hopes to treat obesity","volume":"127","author":"Hawkins","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/biom10060855","article-title":"Targeting the endocannabinoid CB1 receptor to treat body weight disorders: a preclinical and clinical review of the therapeutic potential of past and present CB1 drugs","volume":"10","author":"Murphy","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.numecd.2022.02.016_bib90","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2022.02.016_bib91","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2022.02.016_bib92","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ijo.2012.116","article-title":"CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans","volume":"37","author":"Bergholm","year":"2013","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib93","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2337\/dc09-0455","article-title":"Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial","volume":"33","author":"Hollander","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib94","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ijo.2010.38","article-title":"A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study","volume":"34","author":"Proietto","year":"2010","journal-title":"Int J Obes"},{"issue":"5","key":"10.1016\/j.numecd.2022.02.016_bib95","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"Int J Obes"},{"issue":"1\u20133","key":"10.1016\/j.numecd.2022.02.016_bib96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(03)01343-8","article-title":"Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice","volume":"462","author":"Hildebrandt","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib97","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.metabol.2013.06.011","article-title":"Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats","volume":"62","author":"Merroun","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2022.02.016_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3389\/fimmu.2019.01049","article-title":"Cannabinoid receptor 1 blockade attenuates obesity and adipose tissue type 1 inflammation through miR-30e-5p regulation of delta-like-4 in macrophages and consequently downregulation of Th1 cells","volume":"10","author":"Miranda","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib99","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.12141","article-title":"Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib100","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1096\/fj.201801152RR","article-title":"A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice","volume":"33","author":"Han","year":"2019","journal-title":"Faseb J"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib101","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/hep.30364","article-title":"Cannabinoid-1 receptor antagonism improves glycemic control and increases energy expenditure through sirtuin-1\/mechanistic target of rapamycin complex 2 and 5\u2019Adenosine monophosphate-activated protein kinase signaling","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"issue":"Pt A","key":"10.1016\/j.numecd.2022.02.016_bib102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phrs.2016.08.012","article-title":"The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism","volume":"113","author":"Fois","year":"2016","journal-title":"Pharmacol Res"},{"issue":"1\u20132","key":"10.1016\/j.numecd.2022.02.016_bib103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(01)00873-1","article-title":"Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2","volume":"416","author":"Aceto","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.numecd.2022.02.016_bib104","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12659\/MSMBR.883726","article-title":"Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2","volume":"19","author":"Radziszewska","year":"2013","journal-title":"Med Sci Monit Basic Res"},{"issue":"7","key":"10.1016\/j.numecd.2022.02.016_bib105","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.numecd.2022.02.016_bib106","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/nutd.2013.9","article-title":"The cannabinoid \u0394(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity","volume":"3","author":"Wargent","year":"2013","journal-title":"Nutr Diabetes"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib107","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib108","doi-asserted-by":"crossref","first-page":"pyv092","DOI":"10.1093\/ijnp\/pyv092","article-title":"The CB1 neutral antagonist tetrahydrocannabivarin reduces default mode network and increases executive control network resting state functional connectivity in healthy volunteers","volume":"19","author":"Rzepa","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib109","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41366-019-0334-z","article-title":"Medical marijuana-an obesity problem or opportunity?","volume":"43","author":"Greenway","year":"2019","journal-title":"Int J Obes"},{"key":"10.1016\/j.numecd.2022.02.016_bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2014.08.065","article-title":"Serotonin controlling feeding and satiety","volume":"277","author":"Voigt","year":"2015","journal-title":"Behav Brain Res"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib111","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40265-018-0946-y","article-title":"Centrally acting agents for obesity: past, present, and future","volume":"78","author":"Coulter","year":"2018","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.numecd.2022.02.016_bib112","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMp2003873","article-title":"Cancer risk associated with lorcaserin - the FDA's review of the CAMELLIA-TIMI 61 trial","volume":"383","author":"Sharretts","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib113","first-page":"CD011688","article-title":"Fluoxetine for adults who are overweight or obese","volume":"10","author":"Serralde-Z\u00fa\u00f1iga","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","article-title":"A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze","volume":"41","author":"Woolley","year":"2001","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.numecd.2022.02.016_bib115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjp.0706807","article-title":"Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats","volume":"148","author":"Fisas","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.numecd.2022.02.016_bib116","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11011-015-9736-3","article-title":"Idalopirdine \u2013 a small molecule antagonist of 5-HT6 with therapeutic potential against obesity","volume":"30","author":"Dudek","year":"2015","journal-title":"Metab Brain Dis"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib117","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11011-017-0175-1","article-title":"Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating","volume":"33","author":"Kota\u0144ska","year":"2018","journal-title":"Metab Brain Dis"},{"issue":"5900","key":"10.1016\/j.numecd.2022.02.016_bib118","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.1161550","article-title":"Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele","volume":"322","author":"Stice","year":"2008","journal-title":"Science"},{"issue":"9253","key":"10.1016\/j.numecd.2022.02.016_bib119","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.numecd.2022.02.016_bib120","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.neuroimage.2008.06.002","article-title":"Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors","volume":"42","author":"Volkow","year":"2008","journal-title":"Neuroimage"},{"issue":"10","key":"10.1016\/j.numecd.2022.02.016_bib121","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1172\/JCI129195","article-title":"CNS-targeting pharmacological interventions for the metabolic syndrome","volume":"129","author":"Stemmer","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib122","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41398-020-01055-2","article-title":"Recovering from depression with repetitive transcranial magnetic stimulation (rTMS): a systematic review and meta-analysis of preclinical studies","volume":"10","author":"De Risio","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.numecd.2022.02.016_bib123","doi-asserted-by":"crossref","first-page":"106760","DOI":"10.1016\/j.addbeh.2020.106760","article-title":"Transcranial Magnetic Stimulation: a review about its efficacy in the treatment of alcohol, tobacco and cocaine addiction","volume":"114","author":"Antonelli","year":"2021","journal-title":"Addict Behav"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib124","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/erv.2256","article-title":"A systematic review of the effects of neuromodulation on eating and body weight: evidence from human and animal studies","volume":"21","author":"McClelland","year":"2013","journal-title":"Eur Eat Disord Rev"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib125","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/dom.13741","article-title":"Weight loss induced by deep transcranial magnetic stimulation in obesity: a randomized, double-blind, sham-controlled study","volume":"21","author":"Ferrulli","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib126","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12020-020-02496-x","article-title":"Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity","volume":"71","author":"Ferrulli","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib127","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.numecd.2021.02.015","article-title":"Repetitive deep TMS for the reduction of body weight: bimodal effect on the functional brain connectivity in \u201cdiabesity\u201d","volume":"31","author":"Devoto","year":"2021","journal-title":"Nutr Metabol Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib128","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/dom.13763","article-title":"The effects of high-frequency repetitive transcranial magnetic stimulation on resting-state functional connectivity in obese adults","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.numecd.2022.02.016_bib129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12020-021-02802-1","article-title":"Reduction of impulsivity in patients receiving deep transcranial magnetic stimulation treatment for obesity","volume":"74","author":"Luzi","year":"2021","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.numecd.2022.02.016_bib130","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.3390\/ijms22094692","article-title":"Deep transcranial magnetic stimulation affects gut microbiota composition in obesity: results of randomized clinical trial","volume":"22","author":"Ferrulli","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0893-133X(00)00099-3","article-title":"Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain","volume":"23","author":"M\u00fcller","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib132","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-018-1791-1","article-title":"High frequency deep transcranial magnetic stimulation acutely increases \u03b2-endorphins in obese humans","volume":"64","author":"Ferrulli","year":"2019","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib133","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.brs.2019.07.020","article-title":"The effects of repetitive transcranial magnetic stimulation on body weight and food consumption in obese adults: a randomized controlled study","volume":"12","author":"Kim","year":"2019","journal-title":"Brain Stimul"},{"issue":"2","key":"10.1016\/j.numecd.2022.02.016_bib134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.15605\/jafes.035.02.06","article-title":"Efficacy of repetitive transcranial magnetic stimulation (rTMS)in inducing weight loss among obese Filipino patients:A randomized controlled trial","volume":"35","author":"Encarnacion","year":"2020","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"8","key":"10.1016\/j.numecd.2022.02.016_bib135","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41366-021-00833-2","article-title":"Efficacy and acceptability of noninvasive brain stimulation interventions for weight reduction in obesity: a pilot network meta-analysis","volume":"45","author":"Zeng","year":"2021","journal-title":"Int J Obes"},{"key":"10.1016\/j.numecd.2022.02.016_bib136","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/1028415X.2018.1470371","article-title":"Is transcranial direct current stimulation an effective modality in reducing food craving? A systematic review and meta-analysis","volume":"23","author":"Mostafavi","year":"2018","journal-title":"Nutr Neurosci"},{"issue":"6","key":"10.1016\/j.numecd.2022.02.016_bib137","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41366-020-0545-3","article-title":"Noninvasive neuromodulation of the prefrontal cortex in young women with obesity: a randomized clinical trial","volume":"44","author":"Fassini","year":"2020","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.numecd.2022.02.016_bib138","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/a-1198-8525","article-title":"Ergogenic effects of bihemispheric transcranial direct current stimulation on fitness: a randomized cross-over trial","volume":"42","author":"Codella","year":"2021","journal-title":"Int J Sports Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475322001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475322001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:21:51Z","timestamp":1760545311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475322001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":138,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0939475322001041"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2022.02.016","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Turning the clock forward: New pharmacological and non pharmacological targets for the treatment of obesity","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2022.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}